In 2023, Chiesi Group reported a significant milestone with sales reaching over €3 billion, representing a growth of 10% compared to the previous year. This growth was primarily driven by the Rare business unit, which saw a remarkable increase of 65% at constant exchange rates (CER). The company also maintained a steady profitability of around 30% for the fourth consecutive year, enabling it to continue its expansion strategy.
A key highlight of Chiesi’s performance in 2023 was its focus on research and development (R&D), with 24% of total sales dedicated to creating innovative therapeutic solutions. This investment in R&D was aimed at meeting the needs of patients, caregivers, and the healthcare community overall, showcasing Chiesi’s commitment to driving impactful change in the industry.
Furthermore, the company saw growth across all three of its business areas (AIR, RARE, and CARE) and in all its regions, with the US, Europe, China, and International markets all showing positive trends. The emphasis on innovation remained central to Chiesi’s growth strategy, with investments in both internal pipeline development and external collaborations.
The AIR franchise, focused on respiratory diseases, continued to be a significant contributor to Chiesi’s sales, with a 6% growth at CER. The company’s products for asthma and COPD treatment saw strong performance in 2023, with notable partnerships and new treatments entering the market.
In the RARE diseases business unit, Chiesi achieved significant sales growth, surpassing €500 million, driven by organic expansion and strategic acquisitions. The company obtained various regulatory approvals for treatments targeting rare and ultra-rare genetic diseases, further expanding its impact on patients in need.
In the CARE franchise, which includes specialty care, neonatology, and consumer healthcare, Chiesi saw consistent growth, particularly in critical care products. The company’s commitment to developing solutions for premature infants and newborns continued to drive positive outcomes and advancements in the healthcare landscape.
With a strong focus on sustainability and ethical standards, Chiesi maintained its dedication to combatting climate change and achieving Net-Zero greenhouse gas emissions by 2035. The company was recognized for its commitment to sustainability through various certifications and ratings, highlighting its leadership in environmental responsibility.
Looking ahead to 2024, Chiesi aims to continue its growth trajectory with a focus on strategic acquisitions, R&D investments, and expanding its value proposition in key therapeutic areas. The company’s commitment to sustainability, innovation, and patient care positions it as a leader in the biopharmaceutical industry, dedicated to creating shared value for society and driving positive change.
Source link
